Enhanced controllable triplet proximity effect in superconducting spin–orbit coupled spin valves with modified superconductor/ferromagnet interfaces

In a superconductor/ferromagnet hybrid, a magnetically controlled singlet-to-triplet Cooper pair conversion can modulate the superconducting critical temperature. In these triplet superconducting spin valves, such control usually requires inhomogeneous magnetism. However, in the presence of spin–orbit coupling from an interfacial heavy metal layer, the singlet/triplet conversion rate and, thus, critical temperature can be controlled via the magnetization direction of a single homogeneous ferromagnet. Here, we report significantly enhanced controllable pair conversion to a triplet state in a Nb/Pt/Co/Pt superconducting spin valve in which Pt/Co/Pt is homogenously magnetized and proximity-coupled to a superconducting layer of Nb. The Co/Pt interface furthest away from Nb is modified by a sub-nanometer-thick layer of Cu or Au. We argue that the enhancement is most likely associated from an improvement of the Co/Pt interface due to the insertion of Cu and Au layers. Additionally, the higher normalized orbital moments in Au measured using x-ray magnetic circular dichroism shows that increasing spin–orbit coupling enhances the triplet proximity effect—an observation supported by our theoretical calculations. Our results provide a pathway to enhancing triplet pair creation by interface engineering for device development in superspintronics.</p

Irbesartan in Marfan syndrome (AIMS): a double-blind, placebo-controlled randomised trial

Background: Irbesartan, a long acting selective angiotensin-1 receptor inhibitor, in Marfan syndrome might reduce aortic dilatation, which is associated with dissection and rupture. We aimed to determine the effects of irbesartan on the rate of aortic dilatation in children and adults with Marfan syndrome. Methods: We did a placebo-controlled, double-blind randomised trial at 22 centres in the UK. Individuals aged 6–40 years with clinically confirmed Marfan syndrome were eligible for inclusion. Study participants were all given 75 mg open label irbesartan once daily, then randomly assigned to 150 mg of irbesartan (increased to 300 mg as tolerated) or matching placebo. Aortic diameter was measured by echocardiography at baseline and then annually. All images were analysed by a core laboratory blinded to treatment allocation. The primary endpoint was the rate of aortic root dilatation. This trial is registered with ISRCTN, number ISRCTN90011794. Findings: Between March 14, 2012, and May 1, 2015, 192 participants were recruited and randomly assigned to irbesartan (n=104) or placebo (n=88), and all were followed for up to 5 years. Median age at recruitment was 18 years (IQR 12–28), 99 (52%) were female, mean blood pressure was 110/65 mm Hg (SDs 16 and 12), and 108 (56%) were taking β blockers. Mean baseline aortic root diameter was 34·4 mm in the irbesartan group (SD 5·8) and placebo group (5·5). The mean rate of aortic root dilatation was 0·53 mm per year (95% CI 0·39 to 0·67) in the irbesartan group compared with 0·74 mm per year (0·60 to 0·89) in the placebo group, with a difference in means of −0·22 mm per year (−0·41 to −0·02, p=0·030). The rate of change in aortic Z score was also reduced by irbesartan (difference in means −0·10 per year, 95% CI −0·19 to −0·01, p=0·035). Irbesartan was well tolerated with no observed differences in rates of serious adverse events. Interpretation: Irbesartan is associated with a reduction in the rate of aortic dilatation in children and young adults with Marfan syndrome and could reduce the incidence of aortic complications